A PHASE 3 OPEN-LABEL, MULTI-CENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
Latest Information Update: 06 Dec 2024
At a glance
- Drugs Ritlecitinib (Primary)
- Indications Vitiligo
- Focus Adverse reactions; Registrational
- Acronyms Tranquillo LTE
- Sponsors Pfizer
- 26 Jun 2024 Planned End Date changed from 8 Aug 2026 to 30 Jan 2027.
- 26 Jun 2024 Planned primary completion date changed from 8 Aug 2026 to 30 Jan 2027.
- 29 Jan 2024 Planned End Date changed from 7 Aug 2026 to 8 Aug 2026.